Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Primary Immunodeficiency Disease
- Main trialPhase 3
- “This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)”In the company’s words, NCT02810444 on ClinicalTrials.gov
Other drugs for Primary Immunodeficiency Disease
- PanzygaOctapharma · Phase 3
- IVIG-VImmuneVirchow Group · Phase 3
- DonidalorsenIonis Pharmaceuticals, Inc. · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- NavenibartAstria Therapeutics, Inc. · Phase 3
- DeucrictibantPharvaris Netherlands B.V. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 1 Apr 2020 | Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026